牛牛AI助理已提取核心訊息
On February 16, 2024, Incannex Healthcare Inc., a biotechnology company specializing in cannabinoid and psychedelic medicine, announced the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for their product CannQuit-N, a novel tobacco smoking cessation solution. The meeting involved discussions on the regulatory aspects of CannQuit-N's development program, with the FDA providing recommendations on clinical trial design, including efficacy and safety endpoints, and confirming the appropriateness of manufacturing and quality control strategies. CannQuit-N is a medicated chewing gum that combines cannabidiol (CBD) with nicotine, aiming to assist smokers in quitting more effectively than traditional nicotine replacement therapies. Incannex holds patents for this combination and anticipates growth in the nicotine replacement therapy market. The company is also developing treatments for various conditions, including obstructive sleep apnoea and traumatic brain injury, with a strong patent strategy and 19 granted patents. This announcement was approved by Incannex's Board of Directors for release to NASDAQ.
On February 16, 2024, Incannex Healthcare Inc., a biotechnology company specializing in cannabinoid and psychedelic medicine, announced the successful completion of a pre-IND meeting with the U.S. Food and Drug Administration (FDA) for their product CannQuit-N, a novel tobacco smoking cessation solution. The meeting involved discussions on the regulatory aspects of CannQuit-N's development program, with the FDA providing recommendations on clinical trial design, including efficacy and safety endpoints, and confirming the appropriateness of manufacturing and quality control strategies. CannQuit-N is a medicated chewing gum that combines cannabidiol (CBD) with nicotine, aiming to assist smokers in quitting more effectively than traditional nicotine replacement therapies. Incannex holds patents for this combination and anticipates growth in the nicotine replacement therapy market. The company is also developing treatments for various conditions, including obstructive sleep apnoea and traumatic brain injury, with a strong patent strategy and 19 granted patents. This announcement was approved by Incannex's Board of Directors for release to NASDAQ.
2024年2月16日，專門從事大麻素和迷幻藥物的生物技術公司Incannex Healthcare Inc. 宣佈成功完成了與美國食品藥品監督管理局（FDA）就其產品Cannquit-N（一種新型菸草戒菸解決方案）舉行的IND前會議。會議討論了Cannquit-N開發計劃的監管方面，美國食品藥品管理局就臨床試驗設計提供了建議，包括療效和安全終點，並確認了製造和質量控制策略的適當性。Cannquit-n是一種藥用口香糖，它結合了大麻二酚（CBD）和尼古丁，旨在比傳統的尼古丁替代療法更有效地幫助吸菸者戒菸。Incannex擁有這種組合的專利，並預計尼古丁替代療法市場的增長。該公司還在開發各種疾病的治療方法，包括阻塞性睡眠呼吸暫停和創傷性腦損傷，擁有強大的專利戰略和19項已獲授權的專利。該公告已獲得Incannex董事會的批准，將在納斯達克發佈。
2024年2月16日，專門從事大麻素和迷幻藥物的生物技術公司Incannex Healthcare Inc. 宣佈成功完成了與美國食品藥品監督管理局（FDA）就其產品Cannquit-N（一種新型菸草戒菸解決方案）舉行的IND前會議。會議討論了Cannquit-N開發計劃的監管方面，美國食品藥品管理局就臨床試驗設計提供了建議，包括療效和安全終點，並確認了製造和質量控制策略的適當性。Cannquit-n是一種藥用口香糖，它結合了大麻二酚（CBD）和尼古丁，旨在比傳統的尼古丁替代療法更有效地幫助吸菸者戒菸。Incannex擁有這種組合的專利，並預計尼古丁替代療法市場的增長。該公司還在開發各種疾病的治療方法，包括阻塞性睡眠呼吸暫停和創傷性腦損傷，擁有強大的專利戰略和19項已獲授權的專利。該公告已獲得Incannex董事會的批准，將在納斯達克發佈。
有用
沒用